Protein A resin is the key chromatography material used in the production and purification of monoclonal antibodies. Monoclonal antibodies are extensively used drugs for conditions including cancer, autoimmune disorders, and other chronic ailments. Their demand has been rising at a steady pace owing to growing antibody drug approvals and market acceptance of targeted immunotherapies. Protein A resin is immobilized on cross-linked agarose beads and selectively binds immunoglobulin G (IgG) antibodies from complex biological samples. Some key advantages include high specificity for IgG and batch-to-batch consistency to efficiently and cost-effectively purify and isolate monoclonal antibodies on an industrial scale.

The global Protein A Resin Market is estimated to be valued at US$ 474.0 Mn in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/protein-a-resin-market-231

Market key trends:

One of the major trends witnessed in the Protein A resin market has been the development of monolithic protein A chromatography media. This involves replacing the traditional agrose-based stationary phase with a pillar array chip to achieve higher binding capacity, faster flow rates and lower operating costs compared to bead-based resins. Companies are innovating in the area of monoliths to achieve process intensification for large-scale antibody manufacturing. Another notable trend is the production of protein A resins from alternative immobilization matrices like silica to overcome limitations of agarose such as inconsistent ligand density. This has potential to lower costs without compromising on performance standards. Regulatory approval of biosimilar drugs is also augmenting resin demand as it enables monoclonal antibody production at reduced prices for widespread patient access.

Porter’s Analysis

Threat of new entrants: Existing players focus significantly on R&D to differentiate their products and cater to niche requirements, making it difficult for new players to enter the market. They enjoy economies of scale and have established global distribution networks.
Bargaining power of buyers: Buyers have moderate bargaining power as they can negotiate prices to some extent due to the availability of substitutes. However, the specialized nature of protein A resins restricts this bargaining power to a certain extent.
Bargaining power of suppliers: The suppliers of raw materials used to manufacture protein A resins have moderate bargaining power due to the specialized availability and established supplier relationships of key players.

Threat of new substitutes: There exists a threat of new substitutes that can cater to specific purification requirements. However, the industry leverages ongoing product innovation to enhance performance and functionality, limiting major threats.
Competitive rivalry: The market is highly competitive with the presence of a few large players. Key strategies adopted are new product launches, partnerships and acquisitions to expand their regional presence.

Key Takeaways

The global protein A resin market is expected to witness high growth over the forecast period supported by the growing adoption of protein-based therapeutics. The global Protein A Resin Market is estimated to be valued at US$ 474.0 Mn in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period 2023 to 2030.

Regional analysis: North America dominated the market in 2020 and is expected to maintain its leading position throughout the forecast period driven by increased biopharmaceutical R&D expenditures and adoption of protein therapeutics in the region. Asia Pacific is projected to witness the fastest growth rate during the analysis period supported by lucrative opportunities in emerging biologics manufacturing hubs such as China and India.

Key players: Key players operating in the protein A resin market are GE Healthcare, Thermo Fisher Scientific, Repligen, Tosoh Bioscience, EMD Millipore, Novasep, GenScript Biotech Corporation, Purolite Life Sciences, and Expedeon Ltd. Players are focusing on new product launches and partnerships to strengthen their geographic presence.